Linagliptin Inpatient Trial
Linagliptin Inpatient Trial: A Randomized Controlled Trial on the Safety and Efficacy of Linagliptin (Tradjenta®) Therapy for the Inpatient Management of General Surgery Patients With Type 2 Diabetes
Sponsor: Boston Medical Center
This PHASE4 trial investigates Type 2 Diabetes and is currently completed. Boston Medical Center leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE4
-
Nov 2018 — Mar 2019 [monthly]
Completed PHASE4
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE4
-
Apr 2017 — Jun 2018 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Jan 2017 — Apr 2017 [monthly]
Recruiting PHASE4
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Medical Center
- Emory University
- Rush University
- University of Denver
For direct contact, visit the study record on ClinicalTrials.gov .